FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282969401> ?p ?o ?g. }

• W4282969401 endingPage "2869" @default.
• W4282969401 startingPage "2869" @default.
• W4282969401 abstract "Abstract Bispecific T-cell engagers (TCEs) have shown therapeutic promise in treating hematologic cancers. However, their utility in treating solid tumors has yet to be effectively demonstrated due to on-target off-tumor toxicity and systemic cytokine release syndrome (CRS). To explore the full potential of TCEs as a powerful modality of immunotherapy for solid tumors, we developed ADG138, a novel HER2×CD3 POWERbody™ TCE by applying our SAFEbody® precision masking technology to double mask the binding interfaces in both ADG138 arms using covalently linked designer peptides in order to limit on-target off-tumor toxicities in normal tissues and to avert systemic CRS. In the tumor microenvironment (TME), the double masked ADG138 prodrug can be activated for concomitant in situ binding to the targeted cancer cells by the HER2 arm and to T cells by the CD3 arm to selectively enhance T cell responses against tumor cells specifically. Nonclinical studies demonstrated that when activated, ADG138 was highly potent in inducing T cell mediated cytotoxicity of both high and low HER2-expressing tumor cells in vitro, whereas in its double masked prodrug form ADG138 exhibited high masking efficiency with greatly reduced HER2 binding, T cell activation, and T cell mediated cytotoxicity. In in vivo human PBMC-engrafted tumor xenograft models, ADG138 induced robust tumor regression of both high and low HER2-expressing tumors in mice. Furthermore, combination of ADG138 with our species cross-reactive immuno-oncology therapeutics mediated strong synergistic antitumor activities in HER2 positive syngeneic solid tumor models in human CD3e knock-in mice. The double masked ADG138 prodrug also exhibited excellent safety profiles and normal pharmacokinetics in exploratory toxicology studies in cynomolgus monkeys, achieving over a 300-fold higher tolerated dose in striking contrast with its parental TCE that lacks masking. These nonclinical studies demonstrated that ADG138, a novel double masked HER2×CD3 POWERbody TCE, exhibited an impressively high therapeutic index relative to its parental non-masked TCE in HER2 high and low expressing solid tumors. This provides strong support for advancing the ADG138 prodrug into clinical development for treating HER2-expressing solid tumors as a single agent and in combination with other immune stimulatory agents. Citation Format: Guizhong Liu, Yan Li, Zhengxi Dai, Jiagui Qu, Jianfeng Shi, Qi Zhao, Linhai Qu, Aaron N. Nguyen, Songmao Zheng, Jiangchun Xu, Felix Du, Peter Luo. ADG138, a novel HER2×CD3 POWERbody™ integrating bispecific TCE with precision masking to control cytokine release syndrome and on-target off-tumor toxicity for single agent and combination therapies in HER2-expressing solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2869." @default.
• W4282969401 created "2022-06-17" @default.
• W4282969401 creator A5003058860 @default.
• W4282969401 creator A5004676678 @default.
• W4282969401 creator A5008315200 @default.
• W4282969401 creator A5010334212 @default.
• W4282969401 creator A5023064904 @default.
• W4282969401 creator A5030187457 @default.
• W4282969401 creator A5036191559 @default.
• W4282969401 creator A5038805449 @default.
• W4282969401 creator A5058998106 @default.
• W4282969401 creator A5061919775 @default.
• W4282969401 creator A5068435914 @default.
• W4282969401 creator A5071277762 @default.
• W4282969401 date "2022-06-15" @default.
• W4282969401 modified "2023-09-28" @default.
• W4282969401 title "Abstract 2869: ADG138, a novel HER2×CD3 POWERbody™ integrating bispecific TCE with precision masking to control cytokine release syndrome and on-target off-tumor toxicity for single agent and combination therapies in HER2-expressing solid tumors" @default.
• W4282969401 doi "https://doi.org/10.1158/1538-7445.am2022-2869" @default.
• W4282969401 hasPublicationYear "2022" @default.
• W4282969401 type Work @default.
• W4282969401 citedByCount "0" @default.
• W4282969401 crossrefType "journal-article" @default.
• W4282969401 hasAuthorship W4282969401A5003058860 @default.
• W4282969401 hasAuthorship W4282969401A5004676678 @default.
• W4282969401 hasAuthorship W4282969401A5008315200 @default.
• W4282969401 hasAuthorship W4282969401A5010334212 @default.
• W4282969401 hasAuthorship W4282969401A5023064904 @default.
• W4282969401 hasAuthorship W4282969401A5030187457 @default.
• W4282969401 hasAuthorship W4282969401A5036191559 @default.
• W4282969401 hasAuthorship W4282969401A5038805449 @default.
• W4282969401 hasAuthorship W4282969401A5058998106 @default.
• W4282969401 hasAuthorship W4282969401A5061919775 @default.
• W4282969401 hasAuthorship W4282969401A5068435914 @default.
• W4282969401 hasAuthorship W4282969401A5071277762 @default.
• W4282969401 hasConcept C108215921 @default.
• W4282969401 hasConcept C109316439 @default.
• W4282969401 hasConcept C121608353 @default.
• W4282969401 hasConcept C126322002 @default.
• W4282969401 hasConcept C150903083 @default.
• W4282969401 hasConcept C185592680 @default.
• W4282969401 hasConcept C202751555 @default.
• W4282969401 hasConcept C203014093 @default.
• W4282969401 hasConcept C207001950 @default.
• W4282969401 hasConcept C2776090121 @default.
• W4282969401 hasConcept C2776107976 @default.
• W4282969401 hasConcept C2777701055 @default.
• W4282969401 hasConcept C2778690821 @default.
• W4282969401 hasConcept C2780850621 @default.
• W4282969401 hasConcept C3020616263 @default.
• W4282969401 hasConcept C3875195 @default.
• W4282969401 hasConcept C502942594 @default.
• W4282969401 hasConcept C55493867 @default.
• W4282969401 hasConcept C71924100 @default.
• W4282969401 hasConcept C86803240 @default.
• W4282969401 hasConcept C8891405 @default.
• W4282969401 hasConcept C98274493 @default.
• W4282969401 hasConceptScore W4282969401C108215921 @default.
• W4282969401 hasConceptScore W4282969401C109316439 @default.
• W4282969401 hasConceptScore W4282969401C121608353 @default.
• W4282969401 hasConceptScore W4282969401C126322002 @default.
• W4282969401 hasConceptScore W4282969401C150903083 @default.
• W4282969401 hasConceptScore W4282969401C185592680 @default.
• W4282969401 hasConceptScore W4282969401C202751555 @default.
• W4282969401 hasConceptScore W4282969401C203014093 @default.
• W4282969401 hasConceptScore W4282969401C207001950 @default.
• W4282969401 hasConceptScore W4282969401C2776090121 @default.
• W4282969401 hasConceptScore W4282969401C2776107976 @default.
• W4282969401 hasConceptScore W4282969401C2777701055 @default.
• W4282969401 hasConceptScore W4282969401C2778690821 @default.
• W4282969401 hasConceptScore W4282969401C2780850621 @default.
• W4282969401 hasConceptScore W4282969401C3020616263 @default.
• W4282969401 hasConceptScore W4282969401C3875195 @default.
• W4282969401 hasConceptScore W4282969401C502942594 @default.
• W4282969401 hasConceptScore W4282969401C55493867 @default.
• W4282969401 hasConceptScore W4282969401C71924100 @default.
• W4282969401 hasConceptScore W4282969401C86803240 @default.
• W4282969401 hasConceptScore W4282969401C8891405 @default.
• W4282969401 hasConceptScore W4282969401C98274493 @default.
• W4282969401 hasIssue "12_Supplement" @default.
• W4282969401 hasLocation W42829694011 @default.
• W4282969401 hasOpenAccess W4282969401 @default.
• W4282969401 hasPrimaryLocation W42829694011 @default.
• W4282969401 hasRelatedWork W1592261125 @default.
• W4282969401 hasRelatedWork W1982027601 @default.
• W4282969401 hasRelatedWork W200909032 @default.
• W4282969401 hasRelatedWork W2083651068 @default.
• W4282969401 hasRelatedWork W2464301138 @default.
• W4282969401 hasRelatedWork W2517050254 @default.
• W4282969401 hasRelatedWork W2783157092 @default.
• W4282969401 hasRelatedWork W2903959696 @default.
• W4282969401 hasRelatedWork W4220725797 @default.
• W4282969401 hasRelatedWork W4309781227 @default.
• W4282969401 hasVolume "82" @default.
• W4282969401 isParatext "false" @default.
• W4282969401 isRetracted "false" @default.
• W4282969401 workType "article" @default.